AbbVie (ABBV) Asset Utilization Ratio (2013 - 2026)
AbbVie (ABBV) reported Asset Utilization Ratio of 0.46 for Q1 2026, up 9.87% year-over-year from 0.42 in Q1 2025, and up 1.74% quarter-over-quarter from 0.46 in Q4 2025.
AbbVie (ABBV) Asset Utilization Ratio (2013 - 2026) Analysis & Trends
AbbVie (ABBV) has 14 years of Asset Utilization Ratio data on file, last reported at 0.46 in Q1 2026.
- Asset Utilization Ratio for Q1 2026 came in at 0.46, up 9.87% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.46 (up 9.87% YoY), and the FY2025 annual result was 0.45, up 8.87% from the prior year.
- Asset Utilization Ratio grew to 0.46 in Q1 2026 per ABBV's latest filing, from 0.46 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.46 in Q1 2026 and troughed at 0.38 in Q2 2024.
- A 5-year average of 0.41 and a median of 0.41 in 2022 frame the typical range for Asset Utilization Ratio.
- The sharpest annual moves came in 2022 and 2024: Asset Utilization Ratio rose 17.43% in 2022, then fell 8.88% in 2024.
- A 5-year view of Asset Utilization Ratio shows it stood at 0.41 in 2022, then declined by 3.26% to 0.4 in 2023, then grew by 0.86% to 0.4 in 2024, then advanced by 12.91% to 0.46 in 2025, then increased by 1.74% to 0.46 in 2026.
- Business Quant data shows ABBV's Asset Utilization Ratio at 0.46 in Q1 2026, 0.46 in Q4 2025, and 0.44 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 0.53 |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 0.63 |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 0.48 |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 0.46 |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 0.50 |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 0.41 |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 0.52 |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 0.12 |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 0.55 |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.46 |
| Dec 31, 2025 | 0.46 |
| Sep 30, 2025 | 0.44 |
| Jun 30, 2025 | 0.43 |
| Mar 31, 2025 | 0.42 |
| Dec 31, 2024 | 0.40 |
| Sep 30, 2024 | 0.39 |
| Jun 30, 2024 | 0.38 |
| Mar 31, 2024 | 0.38 |
| Dec 31, 2023 | 0.40 |
| Sep 30, 2023 | 0.41 |
| Jun 30, 2023 | 0.42 |
| Mar 31, 2023 | 0.42 |
| Dec 31, 2022 | 0.41 |
| Sep 30, 2022 | 0.41 |
| Jun 30, 2022 | 0.40 |
| Mar 31, 2022 | 0.39 |
| Dec 31, 2021 | 0.38 |
| Sep 30, 2021 | 0.37 |
| Jun 30, 2021 | 0.36 |